ClinicalTrials.gg

Program

vebreltinib

Also written as “PLB1001”, “Vebreltinib combined with platinum-based doublet chemotherapy.” and “APL-101 Oral Capsules”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Glioblastoma · Kidney Neoplasms · Glioma, led by 3 companies.

Furthest: phase 3, since Jul 26, 20239 company-led studies, 4 open or runningNext primary completion: Feb 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Beijing Pearl Biotechnology Limited Liability63 open or runningphase 3since Jul 26, 2023Aug 16, 2016Feb 2029phase 3 · NCT06930794
Apollomics21 open or runningphase 2since Jun 1, 2017Jun 1, 2017none ahead
CHABiotech10 open or runningphase 1since Sep 15, 2020Sep 15, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 16, 2016First study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to Beijing Pearl Biotechnology Limited LiabilityBeijing Pearl Biotechnology Limited Liability · NCT02896231 · 37 enrolled · China
  2. Nov 28, 2016Phase 1 study in GliomaBeijing Pearl Biotechnology Limited Liability · NCT02978261 · 18 enrolled · China
  3. Jun 1, 2017Apollomics's first study: phase 2 study in Kidney NeoplasmsNew to ApollomicsApollomics · NCT03175224 · 497 planned · United States, Australia, Canada and more
  4. Feb 3, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungBeijing Pearl Biotechnology Limited Liability · NCT04258033 · 145 enrolled · China
  5. Sep 15, 2020CHABiotech's first study: phase 1 study in Solid TumorNew to CHABiotechCHABiotech · NCT04557306 · 6 enrolled · Korea, Republic of
  6. May 3, 2022Phase 1 study in BioequivalenceApollomics · NCT05367388 · 48 enrolled · New Zealand
  7. Jul 26, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungBeijing Pearl Biotechnology Limited Liability · NCT05989542 · 136 planned · China
  8. Oct 24, 2023Phase 3 study in GlioblastomaBeijing Pearl Biotechnology Limited Liability · NCT06105619 · 84 enrolled · China
  9. Feb 27, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungBeijing Pearl Biotechnology Limited Liability · NCT06930794 · 300 planned · China

Ahead

  1. Feb 2029Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungBeijing Pearl Biotechnology Limited Liability · NCT06930794

TargetBeta

MET →read by rule
“An orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) ”NCIt, by rule

Other programs on MET

ProgramCompanyFurthest phaseStudies
cabozantinibruleExelixisphase 436
CrizotinibrulePfizerphase 431
telisotuzumab adizutecanAbbViephase 318
zanzalintinibruleExelixisphase 317
amivantamabruleJohnson & Johnsonphase 316
glumetinibruleHaihe Biopharmaphase 38
vilzemetkibSino Biopharmaceuticalphase 38
dalmelitinibHansoh Pharmaceutical Groupphase 37
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
HS-20117Hansoh Pharmaceutical Groupphase 33
SHR-1826Jiangsu HengRui Medicinephase 27
pamvatamigruleBetta Pharmaceuticalsphase 25

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06930794Carcinoma, Non-Small-Cell Lung · China3RecruitingBeijing Pearl Biotechnology Limited LiabilityFeb 2029300
NCT06105619Glioblastoma · China3Active, not recruitingBeijing Pearl Biotechnology Limited LiabilityApr 1, 202384
NCT05989542Carcinoma, Non-Small-Cell Lung · China3RecruitingBeijing Pearl Biotechnology Limited LiabilitySep 30, 2026136
NCT05367388Bioequivalence · New Zealand1UNKNOWNApollomicsNov 202248
NCT04557306Solid Tumor · Korea, Republic of1CompletedCHABiotechOct 26, 20216
NCT04258033Carcinoma, Non-Small-Cell Lung · China2CompletedBeijing Pearl Biotechnology Limited LiabilityMay 14, 2024145
NCT03175224Kidney Neoplasms · United States, Australia, Canada and more2RecruitingApollomicsMar 30, 2026497
NCT02978261Glioma · China1CompletedBeijing Pearl Biotechnology Limited LiabilityApr 201818
NCT02896231Carcinoma, Non-Small-Cell Lung · China1CompletedBeijing Pearl Biotechnology Limited LiabilityOct 201937

How it is read

Names in the registry

  • “PLB1001”, 5 entries
  • “Vebreltinib combined with platinum-based doublet chemotherapy.”, 1 entry
  • “APL-101 Oral Capsules”, 1 entry
  • “CBT101 cells, every 2 weeks”, 1 entry
  • “CBT101 cells, every 4 weeks”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.